Publications by authors named "Rajesh Srinivas"
Article Synopsis
- Chronic Limb Threatening Ischemia (CLTI) is a severe condition leading to high rates of limb amputation and cardiovascular death, particularly in cases where standard treatments fail.
- Endovascular interventions are the main treatment strategy, but a significant number of patients are considered "no-option," prompting interest in new therapies like bone marrow-derived mesenchymal stromal cells (BM-MSC).
- REGENACIP is an approved BM-MSC therapy in India for patients with critical limb ischemia who are not candidates for traditional revascularization, and this review discusses its potential benefits and effectiveness in treating CLTI.
Peripheral artery disease (PAD), a significant health burden worldwide, affects lower extremities due to atherosclerosis in peripheral vessels. Although the mechanisms of PAD have been well studied, the molecular milieu of the plaques localized within peripheral arteries are not well understood. Thus, to identify PAD-lesion-specific gene expression profiles precluding genetic, environmental, and dietary biases, we studied the transcriptomic profile of nine plaque tissues normalized to non-plaque tissues from the same donors.
View Article and Find Full Text PDFObjective: We describe a new technique of valve leaflet closure, reduction internal valvuloplasty (RIVAL), to treat primary deep vein valvular incompetence in patients with C6 venous disease.
Methods: The RIVAL method involves excision of redundant valve and suturing of the freshened edge to the wall of the valve station instead of plication at the commissural junctions. Since January 2008, RIVAL has been successfully performed on 44 incompetent deep vein valves in 18 consecutive patients (25 limbs).